Investigational Drug Information for Peposertib
✉ Email this page to a colleague
What is the development status for investigational drug Peposertib?
Peposertib is an investigational drug.
There have been 15 clinical trials for Peposertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 23rd 2019.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck KGaA, Darmstadt, Germany, and Merck KGaA.
There are four US patents protecting this investigational drug and one hundred and twenty-six international patents.
Summary for Peposertib
| US Patents | 4 |
| International Patents | 126 |
| US Patent Applications | 53 |
| WIPO Patent Applications | 45 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 1 (2019-12-23) |
| Vendors | 23 |
Recent Clinical Trials for Peposertib
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | National Cancer Institute (NCI) | Phase 1 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | National Cancer Institute (NCI) | Phase 1 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Peposertib
Top disease conditions for Peposertib
Top clinical trial sponsors for Peposertib
US Patents for Peposertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Peposertib | ⤷ Sign Up | Arylquinazolines | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| Peposertib | ⤷ Sign Up | Arylquinazolines | Merk Patent GMBH (Darmstadt, DE) | ⤷ Sign Up |
| Peposertib | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Peposertib | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Peposertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Peposertib | Argentina | AR096235 | 2033-05-11 | ⤷ Sign Up |
| Peposertib | Australia | AU2014267723 | 2033-05-11 | ⤷ Sign Up |
| Peposertib | Brazil | BR112015027951 | 2033-05-11 | ⤷ Sign Up |
| Peposertib | Canada | CA2911668 | 2033-05-11 | ⤷ Sign Up |
| Peposertib | Chile | CL2015003285 | 2033-05-11 | ⤷ Sign Up |
| Peposertib | China | CN105358552 | 2033-05-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
